Company: IMNN
Filing Date: 2025-05-19
Form Type: S-1/A
Source: 0001641172-25-011388
Chunk: 28

Company: Imunon, Inc.
Filing Date: 2025-05-19
Form: S-1/A
Chunk 28
---
 March 31, 2025, having a weighted average 
 exercise price of $2.51 per share; and                                                                                    |
| ● | 223,522                                                                                                                   
 shares of Common Stock reserved for future issuance                                                                       
 pursuant to our existing stock incentive plan.                                                                            |

To the extent that any outstanding stock options or warrants are exercised, new stock options are issued under our stock incentive plans, or we otherwise issue additional shares of Common Stock or securities convertible into or exercisable for Common Stock in the future, at a price less than the public offering price, there will be further dilution to new investors.

The information discussed above is illustrative only and will adjust based on the actual public offering price and other terms of this offering determined at pricing. Except as indicated otherwise, the discussion and table above assume no exercise of common warrants offered hereby and no sale of pre-funded warrants, which, if sold, would reduce the number of shares of Common Stock that we are offering on a one-for-one basis. The foregoing discussion and table also does not take into account any “zero exercise price” exercises of the common warrants, pursuant to which a holder of a common warrant has the right to receive an aggregate number of shares equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash rather than a cashless exercise of the common warrant and (ii) 3.0, subject to a limitation on the aggregate number of shares of Common Stock potentially issuable in this offering of 90,000,000 shares of Common Stock.

| 11 |

<div align='center'>USE OF PROCEEDS</div>

We estimate that
we will receive net proceeds from this offering of approximately $7.2 million (assuming the sale of the maximum number of securities
offered hereby), based upon an assumed public offering price of $0.48 per share of Common Stock and accompanying common warrant
(which is the last reported sale price of our Common Stock on Nasdaq on May 16, 2025), after deducting the estimated Placement
Agent fees and estimated offering expenses payable by us and assuming no issuance of any pre-funded warrants and no exercise of the common
warrants. However, because this is a reasonable best-efforts offering with no minimum number of securities or amount of proceeds as a
condition to closing, the actual offering amount, Placement Agent fees, and net proceeds to us are not presently determinable and may
be substantially less than the maximum amounts set forth on the cover page